4/10
09:00 am
cytk
Cytokinetics (CYTK) is now covered by Wells Fargo & Company. They set an "overweight" rating and a $95.00 price target on the stock.
Low
Report
Cytokinetics (CYTK) is now covered by Wells Fargo & Company. They set an "overweight" rating and a $95.00 price target on the stock.
4/8
07:16 am
cytk
Cytokinetics (CYTK) was upgraded by Barclays PLC to "strong-buy".
Low
Report
Cytokinetics (CYTK) was upgraded by Barclays PLC to "strong-buy".
4/6
04:00 pm
cytk
Cytokinetics to Participate in the 25th Annual Needham Virtual Healthcare Conference
Low
Report
Cytokinetics to Participate in the 25th Annual Needham Virtual Healthcare Conference
4/6
10:22 am
cytk
Cytokinetics (CYTK) had its price target raised by Barclays PLC from $87.00 to $95.00. They now have an "overweight" rating on the stock.
Low
Report
Cytokinetics (CYTK) had its price target raised by Barclays PLC from $87.00 to $95.00. They now have an "overweight" rating on the stock.
4/4
02:32 pm
cytk
Cytokinetics MYQORZO Approval And CEO Sale Put Valuation In Focus [Yahoo! Finance]
Low
Report
Cytokinetics MYQORZO Approval And CEO Sale Put Valuation In Focus [Yahoo! Finance]
4/3
11:02 am
cytk
Catalyst Watch: OPEC meeting, FedEx talks freight, inflation reads, and SpaceX IPO buzz [Seeking Alpha]
Low
Report
Catalyst Watch: OPEC meeting, FedEx talks freight, inflation reads, and SpaceX IPO buzz [Seeking Alpha]
3/18
04:00 pm
cytk
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Low
Report
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
3/18
02:22 pm
cytk
Cytokinetics (CYTK) had its price target raised by Mizuho from $84.00 to $100.00. They now have an "outperform" rating on the stock.
Low
Report
Cytokinetics (CYTK) had its price target raised by Mizuho from $84.00 to $100.00. They now have an "outperform" rating on the stock.
3/17
10:46 am
cytk
Cytokinetics (CYTK) had its price target raised by JPMorgan Chase & Co. from $74.00 to $75.00. They now have an "overweight" rating on the stock.
Low
Report
Cytokinetics (CYTK) had its price target raised by JPMorgan Chase & Co. from $74.00 to $75.00. They now have an "overweight" rating on the stock.
3/17
12:39 am
cytk
Assessing Cytokinetics (CYTK) Valuation After New MYQORZO Trial Data And Safety Outcomes [Yahoo! Finance]
Medium
Report
Assessing Cytokinetics (CYTK) Valuation After New MYQORZO Trial Data And Safety Outcomes [Yahoo! Finance]
3/16
08:23 am
cytk
Cytokinetics Announces Four Presentations at the American College of Cardiology Annual Scientific Session & Expo [Yahoo! Finance]
Medium
Report
Cytokinetics Announces Four Presentations at the American College of Cardiology Annual Scientific Session & Expo [Yahoo! Finance]
3/16
08:00 am
cytk
Cytokinetics Announces Four Presentations at the American College of Cardiology Annual Scientific Session & Expo
Medium
Report
Cytokinetics Announces Four Presentations at the American College of Cardiology Annual Scientific Session & Expo
3/15
02:10 am
cytk
Cytokinetics Highlights Early MYQORZO Momentum, Eyes Q2 nHCM Phase 3 Catalyst at Barclays Confab [Yahoo! Finance]
Low
Report
Cytokinetics Highlights Early MYQORZO Momentum, Eyes Q2 nHCM Phase 3 Catalyst at Barclays Confab [Yahoo! Finance]
3/15
01:18 am
cytk
Cytokinetics Teases Q2 ACACIA-HCM Catalyst as MYQORZO Launch Gains Momentum at Leerink Conference [Yahoo! Finance]
Low
Report
Cytokinetics Teases Q2 ACACIA-HCM Catalyst as MYQORZO Launch Gains Momentum at Leerink Conference [Yahoo! Finance]
3/15
12:17 am
cytk
Cytokinetics Teases Q2 Phase 3 ACACIA-HCM Readout as Myqorzo Launch Gains Traction at Citi Conference [Yahoo! Finance]
Low
Report
Cytokinetics Teases Q2 Phase 3 ACACIA-HCM Readout as Myqorzo Launch Gains Traction at Citi Conference [Yahoo! Finance]
3/10
01:13 pm
cytk
Cytokinetics (CYTK) was given a new $84.00 price target by Robert W. Baird.
Low
Report
Cytokinetics (CYTK) was given a new $84.00 price target by Robert W. Baird.
3/10
12:06 pm
cytk
Cytokinetics (CYTK) had its "outperform" rating reaffirmed by Leerink Partners.
Low
Report
Cytokinetics (CYTK) had its "outperform" rating reaffirmed by Leerink Partners.
3/9
02:57 pm
cytk
Cytokinetics Insider Exercises Options Worth Over $920,000 as Heart Drug Hits the Market [Yahoo! Finance]
Low
Report
Cytokinetics Insider Exercises Options Worth Over $920,000 as Heart Drug Hits the Market [Yahoo! Finance]
3/6
09:09 am
cytk
Cytokinetics (CYTK) had its "neutral" rating reaffirmed by UBS Group AG.
Medium
Report
Cytokinetics (CYTK) had its "neutral" rating reaffirmed by UBS Group AG.
3/2
04:14 pm
cytk
Cytokinetics to Participate in March Investor Conferences [Yahoo! Finance]
Low
Report
Cytokinetics to Participate in March Investor Conferences [Yahoo! Finance]
3/2
04:00 pm
cytk
Cytokinetics to Participate in March Investor Conferences
Low
Report
Cytokinetics to Participate in March Investor Conferences
3/2
02:28 am
cytk
Assessing Cytokinetics (CYTK) Valuation After Recent Share Price Weakness And Aficamten Expectations [Yahoo! Finance]
Low
Report
Assessing Cytokinetics (CYTK) Valuation After Recent Share Price Weakness And Aficamten Expectations [Yahoo! Finance]
2/26
02:56 pm
cytk
Cytokinetics (CYTK) had its price target raised by Leerink Partners from $83.00 to $84.00. They now have an "outperform" rating on the stock.
Low
Report
Cytokinetics (CYTK) had its price target raised by Leerink Partners from $83.00 to $84.00. They now have an "outperform" rating on the stock.
2/25
07:05 pm
cytk
Cytokinetics (CYTK) had its "neutral" rating reaffirmed by Bank of America Corporation.
Low
Report
Cytokinetics (CYTK) had its "neutral" rating reaffirmed by Bank of America Corporation.
2/25
08:03 am
cytk
Cytokinetics (CYTK) had its price target raised by Needham & Company LLC from $84.00 to $85.00. They now have a "buy" rating on the stock.
Medium
Report
Cytokinetics (CYTK) had its price target raised by Needham & Company LLC from $84.00 to $85.00. They now have a "buy" rating on the stock.